Categories
Change Password!
Reset Password!
Earlier studies have depicted the function of chemokines in the progress of neuropathy and neuropathic pain disorders. This pilot study aimed to investigate the link between plasma concentrations of chemokines (CXCL9, CXCL10, and CXCL11) and the incidence of diabetic peripheral neuropathy (DPN) in diabetic patients.
CXCL10 levels could
be used as a significant marker for early discovery and application of
therapeutic approaches to recover from and/or prevent diabetic peripheral
neuropathy.
Earlier studies have
depicted the function of chemokines in the progress of neuropathy and
neuropathic pain disorders. This pilot study aimed to investigate the link
between plasma concentrations of chemokines (CXCL9, CXCL10, and CXCL11) and the
incidence of diabetic peripheral neuropathy (DPN) in diabetic patients.
Overall, 73 diabetic
patients were studied. Thirty-six of these patients had DPN and 37 were without
DPN. The Semmes-Weinstein test was used to determine DPN. The Duoset ELISA kits
were used to determine the plasma levels of circulating chemokines.
CXCL10 levels were considerably elevated in individuals having DPN compared to individuals without DPN. Although not statistically significant, the serum levels of CXCL9 were also greater in DPN patients, as shown in Table 1:
Enhanced circulating
levels of CXCL10 were found to be linked with DPN, proposing a role of this
particular chemokine in the development of DPN.
International Journal of Clinical Practice
Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes
Pilar Ascaso et al.
Comments (0)